Currently, there is no effective, safe clinical treatment for sepsis, which accounts for 9.3% of the overall deaths in the United States annually. Sepsis is not only related to infections. Shock, trauma, hemorrhage, and other conditions of critical care contribute to severe sepsis, which is characterized by an overwhelming systemic inflammatory response that causes lethal multiple organ failure. Our goal is to develop novel therapeutic strategies to restrain systemic inflammation and improve survival in experimental sepsis. Treatment with cholinergic agonists such as nicotine, started one day after the onset of the disease, also attenuate systemic inflammation and "rescue" mice from "established" sepsis both in lethal endotoxemia and cecal ligation and puncture. Nicotine has been already used in clinical trials for inflammatory disorders such as ulcerative colitis, but the therapeutic potential of this mechanism is underestimated due to the collateral toxicity of nicotine. There are two fundamental considerations limiting the translational potential of this mechanism in critical care: (1) identification of the specific receptor(s) involved in the process;and (2) identification of the mechanism inhibiting the production of cytokines and pathological markers associated with sepsis. Our studies in RAW264.7 macrophage-like cells indicate that cholinergic agonists inhibit the production of proinflammartory cytokines by modulating NF-kB through a mechanism dependent on the alpha7 nicotinic acethlcholine receptor (nAChR). Since our most recent studies indicate that nicotine attenuates systemic inflammation and improves survival in sham but not in splenectomized mice, we propose to study the implications of these two factors in the spleen. Our objectives are to determine whether cholinergic agonists inhibit a specific step of the NF-kB pathway in the spleen and whether cholinergic agonists modulate NF-kB in the spleen through a mechanism mediated by the alpha7nAChR. If so, specific alpha7nAChR-agonists may represent a promising pharmacological strategy to avoid the toxicity of nicotine and modulate NF-kB in specific immune cells during infectious and inflammatory disorders.

Public Health Relevance

Currently, there is no effective, safe clinical treatment for sepsis, which accounts for 9.3% of the overall deaths in the United States annually. Our goal is to determine the molecular mechanism by which cholinergic agonists restrain systemic inflammation in sepsis. These studies will allow the design of novel pharmacological strategies to improve survival in sepsis

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM084125-05
Application #
8270539
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Dunsmore, Sarah
Project Start
2008-08-05
Project End
2013-06-30
Budget Start
2012-06-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2012
Total Cost
$137,428
Indirect Cost
$49,333
Name
University of Medicine & Dentistry of NJ
Department
Surgery
Type
Schools of Medicine
DUNS #
623946217
City
Newark
State
NJ
Country
United States
Zip Code
07107
Torres-Rosas, Rafael; Yehia, Ghassan; Peña, Geber et al. (2014) Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat Med 20:291-5
Ulloa, Luis (2013) The cholinergic anti-inflammatory pathway meets microRNA. Cell Res 23:1249-50
Cai, Bolin; Dong, Weihong; Sharpe, Susan et al. (2011) Survival and inflammatory responses in experimental models of hemorrhage. J Surg Res 169:257-66
Ulloa, Luis (2011) The anti-inflammatory potential of selective cholinergic agonists. Shock 36:97-8
Pena, Geber; Cai, Bolin; Ramos, Laura et al. (2011) Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis. J Immunol 187:718-25
Vida, Gergely; Peña, Geber; Kanashiro, Alexandre et al. (2011) ?2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. FASEB J 25:4476-85
Vida, Gergely; Pena, Geber; Deitch, Edwin A et al. (2011) ýý7-cholinergic receptor mediates vagal induction of splenic norepinephrine. J Immunol 186:4340-6
Ramos, Laura; Pena, Geber; Cai, Bolin et al. (2010) Mast cell stabilization improves survival by preventing apoptosis in sepsis. J Immunol 185:709-16
Pena, Geber; Cai, Bolin; Liu, Jun et al. (2010) Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis. Eur J Immunol 40:2580-9
Dong, WeiHong; Cai, Bolin; Pena, Geber et al. (2010) Ethyl pyruvate prevents inflammatory responses and organ damage during resuscitation in porcine hemorrhage. Shock 34:205-13

Showing the most recent 10 out of 17 publications